SuPine Notice


  • Rebuilding the Life
    by Redefining the Diseases

  • First-in-class Therapeutics
    for Spinal Cord Injury

Technology

SuPine Therapeutics has developed first-in-class therapeutics for spinal cord injury, which is an incurable condition. SGS101 is an implantable natural polymer-based hydrogel which can be applied in golden-time to protect injured tissue and provide optimal environments for neuroregeneration.

VIEW MORE

SuPine Therapeutics has developed direct conversion technology to generate target cells from somatic cells(e.g. skin cells). Our technology enables the generation of various cell types; iOPCs, iMNs, iHepSCs, iVPCs and iMoPs that are feasible for cell therapy to treat degenerative diseases.

VIEW MORE

SuPine Therapeutics has developed the technology to generate tissue-mimic assembloid by combining ECM-based biomaterials and patient-specific stem cells that are derived by direct conversion.

VIEW MORE

The multi-cell assembloids can be utilized as tissue therapy to replace the injured tissue or lost tissue.

VIEW MORE

The multi-cell assembloids can be utilized as disease models to screen toxicity of the newly developing drugs or to analyze the efficacy of the drugs.

VIEW MORE

About
SuPine Therapeutics

SuPine Therapeutics is developing the first-in-class therapeutics for spinal cord injury to provide patients with better quality of life. We have two innovative platform technologies (natural polymer-based hydrogel, next-generation stem cell therapy). Our ultimate goal is to develop treatments for rare diseases with safety while securing patient's life ethics.

VIEW MORE

Contact Us

  • Address

    Headquarters: (44919) 105 Stem cell research center, 50, UNIST-gil, Eonyang-eup, Ulju-gun, Ulsan, Republic of Korea

    Seoul office: (06180) 518, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea

  • Tel

    052-217-5274

VIEW MORE